---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-041385"
form_type: "8-K"
ticker: "TPST"
cik: "0001544227"
company_name: "Tempest Therapeutics, Inc."
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T17:26:05.475688+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Tempest Q2 2023 net loss $7.6M; TPST-1120 HCC data shows 74% ORR improvement over control

## Summary
- Cash $17.6M at June 30, 2023, down from $31.2M at Dec 31, 2022.
- Net loss Q2 2023 $7.6M ($0.54/share) vs $9.2M ($0.79/share) in Q2 2022.
- TPST-1120 in first-line HCC: unconfirmed ORR 30% (12/40) vs 17.2% (5/29) for control; confirmed ORR 17.5% vs 10.3%.
- 47.5% of TPST-1120 arm patients on treatment vs 23.3% in control; 80% on study vs 50%.
- Expect to discuss updated TPST-1120 data from formal review in H2 2023.

## SEC filing metadata
- accession: 0000950170-23-041385
- form_type: 8-K
- ticker: TPST
- cik: 0001544227
- company_name: Tempest Therapeutics, Inc.
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1544227/000095017023041385/0000950170-23-041385-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1544227/000095017023041385/tpst-20230810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-041385
- JSON: https://secwatch.observer/filing/0000950170-23-041385.json
- Plain text: https://secwatch.observer/filing/0000950170-23-041385.txt

## Key facts
- Earnings Releases
  Tempest Therapeutics, Inc. reported the quarter ended June 30, 2023 results: net income Net loss and net loss per share for the quarter ended June 30, 2023 were $7.6 million and $0.54, respectively, EPS $0.54.
  - Period: the quarter ended June 30, 2023
  - Net income: Net loss and net loss per share for the quarter ended June 30, 2023 were $7.6 million and $0.54, respectively
  - EPS: $0.54
  - Result: reported results
  source text: Net loss and net loss per share for the quarter ended June 30, 2023 were $7.6 million and $0.54, respectively, compared to $9.2 million and $0.79, respectively, for the same period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1544227/000095017023041385/0000950170-23-041385-index.htm
- Earnings Releases
  Tempest Therapeutics, Inc. reported the six months ended June 30, 2023 results: net income Net loss and net loss per share for the six months ended June 30, 2023 were $15.2 million and $1.09, respectively, EPS $1.09.
  - Period: the six months ended June 30, 2023
  - Net income: Net loss and net loss per share for the six months ended June 30, 2023 were $15.2 million and $1.09, respectively
  - EPS: $1.09
  - Result: reported results
  source text: Net loss and net loss per share for the six months ended June 30, 2023 were $15.2 million and $1.09, respectively, compared to $17.7 million and $1.88, respectively, for the same period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1544227/000095017023041385/0000950170-23-041385-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.